Literature DB >> 14763961

Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients.

G R Guillermo1, J F Téllez-Zenteno, N Weder-Cisneros, A Mimenza, B Estañol, J M Remes-Troche, C Cantu-Brito.   

Abstract

OBJECTIVE: To identify the response to thymectomy in patients with seronegative and seropositive myasthenia gravis (SPMG). We analyzed the associated diseases, thymus histology, and the severity of symptoms between the two groups. MATERIAL AND METHODS -
DESIGN: Descriptive, comparative. STUDY UNITS: Fourteen patients with seronegative myasthenia gravis (SNMG) and 57 patients with SPMG who had a thymectomy between 1987 and 1997, with at least 3 years of follow-up. The patients were divided into four groups; (1) Remission, (2) Improvement, (3) No change and (4) Deterioration.
RESULTS: Fourteen patients (20%) were seronegative and 57 were seropositive (80%). In the group of patients with SNMG, three patients were in remission (21%), five with improvement (36%), five with no change (36%) and one with worsening (7%). In the group of patients with SPMG, 12 were in remission (21%), 17 with improvement (30%), 25 with no change (44%) and three (5%) with worsening. The patients with SNMG were older, with less associated diseases and with a lower frequency of thymomas.
CONCLUSIONS: The response to thymectomy was similar between the two groups. It has been suggested that seronegative patients have a better prognosis, but our results show no differences.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14763961     DOI: 10.1034/j.1600-0404.2003.00209.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  9 in total

1.  Commentary on "Randomized trial of thymectomy in myasthenia gravis".

Authors:  Alexandar Tzankov
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

Review 2.  Thymectomy in Myasthenia Gravis.

Authors:  Yener Aydin; Ali Bilal Ulas; Vahit Mutlu; Abdurrahim Colak; Atilla Eroglu
Journal:  Eurasian J Med       Date:  2017-02

Review 3.  Effectiveness of thymectomy in non-thymomatous myasthenia gravis: a systematic review.

Authors:  Yan Luo; Deng-Ji Pan; Fei-Fei Chen; Ming-Hui Zhu; Jing Wang; Min Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06

4.  Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia.

Authors:  Agnes van Sonderen; Paul W Wirtz; Jan J G M Verschuuren; Maarten J Titulaer
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

5.  Somatostatin receptor scintigraphy in the follow-up of myasthenia gravis.

Authors:  Z R Gao; C Kornblum; S Flacke; T Logvinski; M Yüksel; R An; T Klockgether; H J Biersack; S Ezziddin
Journal:  Neurol Sci       Date:  2007-08-10       Impact factor: 3.307

Review 6.  Novel Treatments in Myasthenia Gravis.

Authors:  Deepak Menon; Carolina Barnett; Vera Bril
Journal:  Front Neurol       Date:  2020-06-30       Impact factor: 4.003

Review 7.  Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.

Authors:  Nico Melzer; Tobias Ruck; Peter Fuhr; Ralf Gold; Reinhard Hohlfeld; Alexander Marx; Arthur Melms; Björn Tackenberg; Berthold Schalke; Christiane Schneider-Gold; Fritz Zimprich; Sven G Meuth; Heinz Wiendl
Journal:  J Neurol       Date:  2016-02-17       Impact factor: 4.849

Review 8.  Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.

Authors:  Miriam L Fichtner; Ruoyi Jiang; Aoibh Bourke; Richard J Nowak; Kevin C O'Connor
Journal:  Front Immunol       Date:  2020-05-27       Impact factor: 7.561

Review 9.  [The value of thymectomy in the treatment of non-thymomatous myasthenia gravis].

Authors:  Hruy Menghesha; Michael Schroeter; Fabian Doerr; Georg Schlachtenberger; Matthias B Heldwein; Costanza Chiapponi; Thorsten Wahlers; Christiane Bruns; Khosro Hekmat
Journal:  Chirurg       Date:  2021-06-16       Impact factor: 0.955

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.